Skip to main content
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. — Investor Relations & Filings

Ticker · OKUR ISIN · US75974E1038 US Manufacturing
Open in API
Filings indexed 342 across all filing types
Latest filing 2021-08-26 Director's Dealing
Country US United States of America
Listing US OKUR

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com/

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. The company is building a pipeline of potentially best-in-class, tumor-agnostic therapies that target biologically validated drivers of cancers, particularly those underserved by current treatments. Its research and development efforts are centered on novel and potentially less toxic kinase inhibitor drugs and epigenetic therapies.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-08-26 English
FORM 4 SUBMISSION
Director's Dealing
2021-08-26 English
FORM 4 SUBMISSION
Director's Dealing
2021-08-26 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 11, 2021, by Reneo Pharmaceuticals, Inc. The key content is an update to the company's corporate slide presentation for use in meetings with investors and analysts, which is attached as Exhibit 99.1. The document explicitly states that the presentation is for investor meetings and is furnished under Item 7.01 Regulation FD Disclosure. There is no detailed financial data or comprehensive report content, only a presentation update. According to the filing definitions, a corporate slide presentation for investors focusing on financials, strategy, and market position fits the category of Investor Presentation (IP). The document length is under 5,000 characters, but it includes the presentation itself as an exhibit, not just an announcement of availability, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is Investor Presentation (IP).
2021-08-11 English
10-Q
Interim / Quarterly Report Q2 2021
2021-08-11 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 11, 2021, reporting the company's financial results for the quarter ended June 30, 2021. It references a press release announcing financial results as Exhibit 99.1. The text explicitly states that the information is furnished and not filed, and it is a current report rather than a full quarterly or annual report. The document is short (4063 characters) and primarily serves as an announcement of financial results rather than containing detailed financial statements or analysis. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2021-08-11 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.